<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="publisher-id">diacare</journal-id><journal-title>Diabetes Care</journal-title><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18694978</article-id><article-id pub-id-type="pmc">2571050</article-id><article-id pub-id-type="publisher-id">31112081</article-id><article-id pub-id-type="doi">10.2337/dc08-0509</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></article-categories><title-group><article-title>Is a Priming Dose of Insulin Necessary in a Low-Dose Insulin Protocol for the Treatment of Diabetic Ketoacidosis? </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kitabchi</surname><given-names>Abbas E.</given-names></name><degrees>PHD, MD</degrees><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>Mary Beth</given-names></name><degrees>RN, MS, MBA, CDE</degrees><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Spencer</surname><given-names>Judy</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Matteri</surname><given-names>Robert</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Karas</surname><given-names>Jim</given-names></name><degrees>MS, MS</degrees><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1">From the Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine and Molecular Sciences, University of Tennessee Health Science Center, Memphis, Tennessee</aff><author-notes><fn><p>Corresponding author: Abbas E. Kitabchi, <email>akitabchi@utmem.edu</email></p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2008</year></pub-date><volume>31</volume><issue>11</issue><fpage>2081</fpage><lpage>2085</lpage><history><date date-type="received"><day>11</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Copyright © 2008, American Diabetes Association</copyright-statement><license license-type="open-access"><p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</p></license></permissions><self-uri xlink:title="pdf" xlink:href="zdc01108002081.pdf"></self-uri><abstract><p><bold><offsets xml_i="3151" xml_f="3160" txt_i="11" txt_f="20">OBJECTIVE</offsets></bold><offsets xml_i="3167" xml_f="3338" txt_i="20" txt_f="191">—The purpose of this study was to assess the efficacy of an insulin priming dose with a continuous insulin infusion versus two continuous infusions without a priming dose.</offsets></p><p><bold><offsets xml_i="3351" xml_f="3378" txt_i="192" txt_f="219">RESEARCH DESIGN AND METHODS</offsets></bold><offsets xml_i="3385" xml_f="3459" txt_i="219" txt_f="293">—This prospective randomized protocol used three insulin therapy methods: </offsets><italic><offsets xml_i="3467" xml_f="3468" txt_i="293" txt_f="294">1</offsets></italic><offsets xml_i="3477" xml_f="3599" txt_i="294" txt_f="416">) load group using a priming dose of 0.07 units of regular insulin per kg body weight followed by a dose of 0.07 unit · kg</offsets><sup><offsets xml_i="3604" xml_f="3606" txt_i="416" txt_f="418">−1</offsets></sup><offsets xml_i="3612" xml_f="3616" txt_i="418" txt_f="422"> · h</offsets><sup><offsets xml_i="3621" xml_f="3623" txt_i="422" txt_f="424">−1</offsets></sup><offsets xml_i="3629" xml_f="3684" txt_i="424" txt_f="479"> i.v. in 12 patients with diabetic ketoacidosis (DKA); </offsets><italic><offsets xml_i="3692" xml_f="3693" txt_i="479" txt_f="480">2</offsets></italic><offsets xml_i="3702" xml_f="3784" txt_i="480" txt_f="562">) no load group using an infusion of regular insulin of 0.07 unit · kg body weight</offsets><sup><offsets xml_i="3789" xml_f="3791" txt_i="562" txt_f="564">−1</offsets></sup><offsets xml_i="3797" xml_f="3801" txt_i="564" txt_f="568"> · h</offsets><sup><offsets xml_i="3806" xml_f="3808" txt_i="568" txt_f="570">−1</offsets></sup><offsets xml_i="3814" xml_f="3867" txt_i="570" txt_f="623"> without a loading dose in 12 patients with DKA, and </offsets><italic><offsets xml_i="3875" xml_f="3876" txt_i="623" txt_f="624">3</offsets></italic><offsets xml_i="3885" xml_f="3956" txt_i="624" txt_f="695">) twice no load group using an infusion of regular insulin of 0.14 · kg</offsets><sup><offsets xml_i="3961" xml_f="3963" txt_i="695" txt_f="697">−1</offsets></sup><offsets xml_i="3969" xml_f="3973" txt_i="697" txt_f="701"> · h</offsets><sup><offsets xml_i="3978" xml_f="3980" txt_i="701" txt_f="703">−1</offsets></sup><offsets xml_i="3986" xml_f="4160" txt_i="703" txt_f="877"> without a loading dose in 13 patients with DKA. Outcome was based on the effects of insulin therapy on biochemical and hormonal changes during treatment and recovery of DKA.</offsets></p><p><bold><offsets xml_i="4173" xml_f="4180" txt_i="878" txt_f="885">RESULTS</offsets></bold><offsets xml_i="4187" xml_f="4673" txt_i="885" txt_f="1371">—The load group reached a peak in free insulin value (460 μU/ml) within 5 min and plateaued at 88 μU/ml in 60 min. The twice no load group reached a peak (200 μU/ml) at 45 min. The no load group reached a peak (60 μU/ml) in 60–120 min. Five patients in the no load group required supplemental insulin doses to decrease initial glucose levels by 10%; patients in the twice no load and load groups did not. Except for these differences, times to reach glucose ≤250 mg/dl, pH ≥7.3, and HCO</offsets><sub><offsets xml_i="4678" xml_f="4679" txt_i="1371" txt_f="1372">3</offsets></sub><sup><offsets xml_i="4690" xml_f="4691" txt_i="1372" txt_f="1373">−</offsets></sup><offsets xml_i="4697" xml_f="4760" txt_i="1373" txt_f="1436"> ≥15 mEq/l did not differ significantly among the three groups.</offsets></p><p><bold><offsets xml_i="4773" xml_f="4784" txt_i="1437" txt_f="1448">CONCLUSIONS</offsets></bold><offsets xml_i="4791" xml_f="4939" txt_i="1448" txt_f="1596">—A priming dose in low-dose insulin therapy in patients with DKA is unnecessary if an adequate dose of regular insulin of 0.14 unit · kg body weight</offsets><sup><offsets xml_i="4944" xml_f="4946" txt_i="1596" txt_f="1598">−1</offsets></sup><offsets xml_i="4952" xml_f="4956" txt_i="1598" txt_f="1602"> · h</offsets><sup><offsets xml_i="4961" xml_f="4963" txt_i="1602" txt_f="1604">−1</offsets></sup><offsets xml_i="4969" xml_f="5017" txt_i="1604" txt_f="1652"> (about 10 units/h in a 70-kg patient) is given.</offsets></p></abstract></article-meta><notes><fn-group><fn><p>Published ahead of print at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org">http://care.diabetesjournals.org</ext-link> on 11 August 2008.</p><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.</p></fn></fn-group></notes></front><body><p><offsets xml_i="5515" xml_f="5657" txt_i="1660" txt_f="1802">Although positive therapeutic responses to low-dose insulin therapy have been established in adult patients with diabetic ketoacidosis (DKA) (</offsets><xref ref-type="bibr" rid="r1"><offsets xml_i="5688" xml_f="5689" txt_i="1802" txt_f="1803">1</offsets></xref><offsets xml_i="5696" xml_f="5697" txt_i="1803" txt_f="1804">–</offsets><xref ref-type="bibr" rid="r8"><offsets xml_i="5728" xml_f="5729" txt_i="1804" txt_f="1805">8</offsets></xref><offsets xml_i="5736" xml_f="5994" txt_i="1805" txt_f="2063">), none of these studies and guidelines for the treatment of DKA, including the American Diabetes Association (ADA) Consensus and Position Statements, has ever assessed or addressed the use of a continuous insulin infusion without a loading dose of insulin (</offsets><xref ref-type="bibr" rid="r9"><offsets xml_i="6025" xml_f="6026" txt_i="2063" txt_f="2064">9</offsets></xref><offsets xml_i="6033" xml_f="6090" txt_i="2064" txt_f="2121">). In the current study, we used a dose of 0.14 unit · kg</offsets><sup><offsets xml_i="6095" xml_f="6097" txt_i="2121" txt_f="2123">−1</offsets></sup><offsets xml_i="6103" xml_f="6107" txt_i="2123" txt_f="2127"> · h</offsets><sup><offsets xml_i="6112" xml_f="6114" txt_i="2127" txt_f="2129">−1</offsets></sup><offsets xml_i="6120" xml_f="6184" txt_i="2129" txt_f="2193"> without a loading dose instead of the recommended 0.1 unit · kg</offsets><sup><offsets xml_i="6189" xml_f="6191" txt_i="2193" txt_f="2195">−1</offsets></sup><offsets xml_i="6197" xml_f="6201" txt_i="2195" txt_f="2199"> · h</offsets><sup><offsets xml_i="6206" xml_f="6208" txt_i="2199" txt_f="2201">−1</offsets></sup><offsets xml_i="6214" xml_f="6350" txt_i="2201" txt_f="2337"> with a loading dose. This insulin regimen was chosen because one study in a pediatric population used a dosing regimen of 0.1 unit · kg</offsets><sup><offsets xml_i="6355" xml_f="6357" txt_i="2337" txt_f="2339">−1</offsets></sup><offsets xml_i="6363" xml_f="6367" txt_i="2339" txt_f="2343"> · h</offsets><sup><offsets xml_i="6372" xml_f="6374" txt_i="2343" txt_f="2345">−1</offsets></sup><offsets xml_i="6380" xml_f="6466" txt_i="2345" txt_f="2431"> without a loading dose that resulted in a total plasma insulin level of 50–60 μU/ml (</offsets><xref ref-type="bibr" rid="r10"><offsets xml_i="6498" xml_f="6500" txt_i="2431" txt_f="2433">10</offsets></xref><offsets xml_i="6507" xml_f="6620" txt_i="2433" txt_f="2546">). This level proved to be too low for optimal suppression of hepatic glucose output and optimal glucose uptake (</offsets><xref ref-type="bibr" rid="r11"><offsets xml_i="6652" xml_f="6654" txt_i="2546" txt_f="2548">11</offsets></xref><offsets xml_i="6661" xml_f="6764" txt_i="2548" txt_f="2651">). In addition, bolus doses of insulin may result in hypokalemia as well as other undesirable effects (</offsets><xref ref-type="bibr" rid="r12"><offsets xml_i="6796" xml_f="6798" txt_i="2651" txt_f="2653">12</offsets></xref><offsets xml_i="6805" xml_f="6859" txt_i="2653" txt_f="2707">), especially when used in a routine hospital setting.</offsets></p><p><offsets xml_i="6866" xml_f="6982" txt_i="2708" txt_f="2824">The efficacy of low-dose insulin without a priming dose has not been established in a prospective randomized study (</offsets><xref ref-type="bibr" rid="r13"><offsets xml_i="7014" xml_f="7016" txt_i="2824" txt_f="2826">13</offsets></xref><offsets xml_i="7023" xml_f="7106" txt_i="2826" txt_f="2909">). Thus, the following questions have remained unanswered in the treatment of DKA: </offsets><italic><offsets xml_i="7114" xml_f="7115" txt_i="2909" txt_f="2910">1</offsets></italic><offsets xml_i="7124" xml_f="7191" txt_i="2910" txt_f="2977">) Is an insulin bolus needed before a continuous insulin infusion? </offsets><italic><offsets xml_i="7199" xml_f="7200" txt_i="2977" txt_f="2978">2</offsets></italic><offsets xml_i="7209" xml_f="7286" txt_i="2978" txt_f="3055">) What is the optimal insulin infusion rate if a bolus dose is not used? and </offsets><italic><offsets xml_i="7294" xml_f="7295" txt_i="3055" txt_f="3056">3</offsets></italic><offsets xml_i="7304" xml_f="7790" txt_i="3056" txt_f="3542">) What is the dose response of continuous insulin infusion used alone in regard to decremental changes in glucose, metabolic parameters, cortisol, and free fatty acids (FFAs)? Therefore, we evaluated responses to three low-dose insulin regimens in 37 consecutive patients with DKA in a prospective randomized fashion to address these issues. Changes in plasma free insulin, serum potassium levels, and outcome recovery measures were assessed using a higher infusion dose (0.14 unit · kg</offsets><sup><offsets xml_i="7795" xml_f="7797" txt_i="3542" txt_f="3544">−1</offsets></sup><offsets xml_i="7803" xml_f="7807" txt_i="3544" txt_f="3548"> · h</offsets><sup><offsets xml_i="7812" xml_f="7814" txt_i="3548" txt_f="3550">−1</offsets></sup><offsets xml_i="7820" xml_f="7894" txt_i="3550" txt_f="3624"> without a bolus dose) compared with a lower infusion dose (0.07 unit · kg</offsets><sup><offsets xml_i="7899" xml_f="7901" txt_i="3624" txt_f="3626">−1</offsets></sup><offsets xml_i="7907" xml_f="7911" txt_i="3626" txt_f="3630"> · h</offsets><sup><offsets xml_i="7916" xml_f="7918" txt_i="3630" txt_f="3632">−1</offsets></sup><offsets xml_i="7924" xml_f="7984" txt_i="3632" txt_f="3692">) with and without a loading dose (0.07 unit/kg) of insulin.</offsets></p><sec><title><offsets xml_i="8000" xml_f="8027" txt_i="3693" txt_f="3720">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="8038" xml_f="8118" txt_i="3721" txt_f="3798">Our criteria for the diagnosis of DKA included plasma glucose &gt;250 mg/dl, HCO</offsets><sub><offsets xml_i="8123" xml_f="8124" txt_i="3798" txt_f="3799">3</offsets></sub><sup><offsets xml_i="8135" xml_f="8136" txt_i="3799" txt_f="3800">−</offsets></sup><offsets xml_i="8142" xml_f="8329" txt_i="3800" txt_f="3981"> &lt;15 mEq/l, pH &lt;7.3, and moderate ketones in the urine or blood by the nitroprusside method. A total of 37 patients were prospectively randomly assigned to three groups as follows: </offsets><italic><offsets xml_i="8337" xml_f="8338" txt_i="3981" txt_f="3982">1</offsets></italic><offsets xml_i="8347" xml_f="8509" txt_i="3982" txt_f="4144">) the load group consisted of 12 patients who received a loading dose of insulin at 0.07 unit/kg body weight followed by an infusion of 0.07 unit · kg body weight</offsets><sup><offsets xml_i="8514" xml_f="8516" txt_i="4144" txt_f="4146">−1</offsets></sup><offsets xml_i="8522" xml_f="8526" txt_i="4146" txt_f="4150"> · h</offsets><sup><offsets xml_i="8531" xml_f="8533" txt_i="4150" txt_f="4152">−1</offsets></sup><offsets xml_i="8539" xml_f="8541" txt_i="4152" txt_f="4154">; </offsets><italic><offsets xml_i="8549" xml_f="8550" txt_i="4154" txt_f="4155">2</offsets></italic><offsets xml_i="8559" xml_f="8696" txt_i="4155" txt_f="4292">) the no load group consisted of 12 patients who received only an intravenous infusion of insulin at a dose of 0.07 unit · kg body weight</offsets><sup><offsets xml_i="8701" xml_f="8703" txt_i="4292" txt_f="4294">−1</offsets></sup><offsets xml_i="8709" xml_f="8713" txt_i="4294" txt_f="4298"> · h</offsets><sup><offsets xml_i="8718" xml_f="8720" txt_i="4298" txt_f="4300">−1</offsets></sup><offsets xml_i="8726" xml_f="8754" txt_i="4300" txt_f="4328"> without a loading dose; or </offsets><italic><offsets xml_i="8762" xml_f="8763" txt_i="4328" txt_f="4329">3</offsets></italic><offsets xml_i="8772" xml_f="8898" txt_i="4329" txt_f="4455">) the twice no load group consisted of 13 patients who received an infusion of insulin at a dose of 0.14 unit · kg body weight</offsets><sup><offsets xml_i="8903" xml_f="8905" txt_i="4455" txt_f="4457">−1</offsets></sup><offsets xml_i="8911" xml_f="8915" txt_i="4457" txt_f="4461"> · h</offsets><sup><offsets xml_i="8920" xml_f="8922" txt_i="4461" txt_f="4463">−1</offsets></sup><offsets xml_i="8928" xml_f="9136" txt_i="4463" txt_f="4671"> without a bolus dose. Responses to therapy were based on the time to achieve a glucose level of ≤250 mg/dl, bicarbonate of ≥15 mEq/l, and pH ≥7.3. All other modes of therapy (hydrating solution, KCl, and HCO</offsets><sub><offsets xml_i="9141" xml_f="9142" txt_i="4671" txt_f="4672">3</offsets></sub><sup><offsets xml_i="9153" xml_f="9154" txt_i="4672" txt_f="4673">−</offsets></sup><offsets xml_i="9160" xml_f="9265" txt_i="4673" txt_f="4778">) were similar in the three groups and followed the recommendations of the first ADA position statement (</offsets><xref ref-type="bibr" rid="r6"><offsets xml_i="9296" xml_f="9297" txt_i="4778" txt_f="4779">6</offsets></xref><offsets xml_i="9304" xml_f="11508" txt_i="4779" txt_f="6977">). All patients were seen in the emergency department of the Regional Medical Center at Memphis. Upon arrival, history was obtained and a physical examination was performed. Urine ketones (by nitroprusside) plus glucose by fingerstick and blood gas measurements were obtained immediately. Once a suspected diagnosis of DKA was made, the initial laboratory blood samples were obtained for basal metabolic parameters and complete blood count with differential; urinalysis was performed for blood and urine ketones by both the nitroprusside and enzymatic methods. Patients then received 1 liter of 0.9% NaCl per hour until laboratory results were available. After laboratory confirmation, the intravenous fluids were adjusted, depending on the glucose and corrected serum sodium value, to ½ N saline or dextrose with 1 N or ½ N saline. With confirmation of the diagnosis of DKA and an acceptable potassium level (&gt;3.3 mEq/l), the patients were then transferred to the Clinical Research Center (CRC) of the University of Tennessee Bowld Hospital after the research study was described to the patients or their next of kin and the consent form, which was approved by the University of Tennessee Health Science Center of Memphis Institutional Review Board, was signed. On arrival at the CRC, the treatment and care of patients was managed by the DKA team, including the medical housestaff on rotation for the service, following an established protocol with consultation of the staff endocrinologist. Hourly blood glucose measurements and blood samples for free insulin were obtained at 0, 5, 15, 30, 45, 60, 120, 240, and 480 min. Blood for measurement of other hormones and ketone bodies, blood gases, and metabolic profile; urinalysis for ketones; and other parameters were obtained. Random assignment of patients to different insulin regimens was done after arrival at the CRC. Random assignment was not based on sex or ethnicity. Because a priming dose of insulin adds an additional risk of hypokalemia, potassium levels were assessed and corrected on an hourly basis for the first few hours of therapy until glucose reached the predetermined goal of &lt;250 mg/dl (i.e., ∼4 h) and every 2 h thereafter.</offsets></p><sec><title><offsets xml_i="11524" xml_f="11545" txt_i="6978" txt_f="6999">Laboratory procedures</offsets></title><p><offsets xml_i="11556" xml_f="12083" txt_i="7000" txt_f="7527">Laboratory studies included complete blood cell count, blood gas measurements, and routine blood chemistry values measured by standard assays in the clinical chemistry laboratory. In addition, plasma free insulin, C-peptide, β-hydroxybutyrate, acetoacetate, pyruvate, lactate, cortisol, and FFAs were assayed. Glucose was measured by a glucose oxidase method using a Beckman glucose analyzer. Plasma free insulin and C-peptide were measured after polyethylene glycol precipitation by a double-antibody radioimmunoassay method (</offsets><xref ref-type="bibr" rid="r14"><offsets xml_i="12115" xml_f="12117" txt_i="7527" txt_f="7529">14</offsets></xref><offsets xml_i="12124" xml_f="12210" txt_i="7529" txt_f="7615">). Cortisol, FFAs, and ketone bodies were determined by previously described methods (</offsets><xref ref-type="bibr" rid="r2"><offsets xml_i="12241" xml_f="12242" txt_i="7615" txt_f="7616">2</offsets></xref><offsets xml_i="12249" xml_f="12250" txt_i="7616" txt_f="7617">,</offsets><xref ref-type="bibr" rid="r15"><offsets xml_i="12282" xml_f="12284" txt_i="7617" txt_f="7619">15</offsets></xref><offsets xml_i="12291" xml_f="12293" txt_i="7619" txt_f="7621">).</offsets></p></sec><sec><title><offsets xml_i="12315" xml_f="12328" txt_i="7623" txt_f="7636">Data analysis</offsets></title><p><offsets xml_i="12339" xml_f="12851" txt_i="7637" txt_f="8149">Overall mean comparisons for means and slopes for the three groups (load, no load, and twice no load) were made with one-way ANOVA using the Clinfo and SAS (SAS Institute, Cary, NC) software packages. These were followed by pairwise comparisons of averages and regression estimates of the slopes by observing the overlap/nonoverlap of the 95% confidence limits for all of the estimates (means and slopes). If any 95% confidence limits for an estimate overlapped, then no statistical significance was declared at </offsets><italic><offsets xml_i="12859" xml_f="12860" txt_i="8149" txt_f="8150">P</offsets></italic><offsets xml_i="12869" xml_f="12968" txt_i="8150" txt_f="8249"> = 0.05. If there was no overlap due to variability, then statistical significance was declared at </offsets><italic><offsets xml_i="12976" xml_f="12977" txt_i="8249" txt_f="8250">P</offsets></italic><offsets xml_i="12986" xml_f="13077" txt_i="8250" txt_f="8338"> &lt; 0.05. This significance and nonsignificance is denoted by superscript letters (as in </offsets><xref ref-type="table" rid="t4"><offsets xml_i="13109" xml_f="13116" txt_i="8338" txt_f="8345">Table 4</offsets></xref><offsets xml_i="13123" xml_f="13192" txt_i="8345" txt_f="8414">). Thus, groups having superscripts in common are not significant at </offsets><italic><offsets xml_i="13200" xml_f="13201" txt_i="8414" txt_f="8415">P</offsets></italic><offsets xml_i="13210" xml_f="13285" txt_i="8415" txt_f="8490"> = 0.05, whereas those having no superscripts in common are significant at </offsets><italic><offsets xml_i="13293" xml_f="13294" txt_i="8490" txt_f="8491">P</offsets></italic><offsets xml_i="13303" xml_f="13314" txt_i="8491" txt_f="8499"> &lt; 0.05.</offsets></p></sec></sec><sec><title><offsets xml_i="13342" xml_f="13349" txt_i="8502" txt_f="8509">RESULTS</offsets></title><sec><title><offsets xml_i="13369" xml_f="13406" txt_i="8510" txt_f="8547">Demographic and initial clinical data</offsets></title><p><xref ref-type="table" rid="t1"><offsets xml_i="13449" xml_f="13456" txt_i="8548" txt_f="8555">Table 1</offsets></xref><offsets xml_i="13463" xml_f="13571" txt_i="8555" txt_f="8663"> shows the baseline characteristics of patients in the three treatment groups, with the following findings: </offsets><italic><offsets xml_i="13579" xml_f="13580" txt_i="8663" txt_f="8664">1</offsets></italic><offsets xml_i="13589" xml_f="13624" txt_i="8664" txt_f="8699">) none of the patients were obese, </offsets><italic><offsets xml_i="13632" xml_f="13633" txt_i="8699" txt_f="8700">2</offsets></italic><offsets xml_i="13642" xml_f="13732" txt_i="8700" txt_f="8790">) the majority of the patients were African Americans and were receiving insulin therapy, </offsets><italic><offsets xml_i="13740" xml_f="13741" txt_i="8790" txt_f="8791">3</offsets></italic><offsets xml_i="13750" xml_f="13848" txt_i="8791" txt_f="8889">) omission of insulin (47%) and infection (33%) were the major precipitating factors for DKA, and </offsets><italic><offsets xml_i="13856" xml_f="13857" txt_i="8889" txt_f="8890">4</offsets></italic><offsets xml_i="13866" xml_f="14154" txt_i="8890" txt_f="9178">) within the load group there were twice as many men as women, within the no load group there were three times as many women as men, and within the twice no load group men and women were equally distributed. However, in all of these groups, the majority of subjects were African American.</offsets></p></sec><sec><title><offsets xml_i="14176" xml_f="14224" txt_i="9180" txt_f="9228">Biochemical data on admission and after recovery</offsets></title><p><xref ref-type="table" rid="t2"><offsets xml_i="14267" xml_f="14274" txt_i="9229" txt_f="9236">Table 2</offsets></xref><offsets xml_i="14281" xml_f="14838" txt_i="9236" txt_f="9793"> shows biochemical data on admission and at complete recovery from DKA in the three groups. Although there were no statistically significant differences among any of the parameters in the groups on admission, cortisol values are lower in the no load group than in the other two groups. It is of interest that all the subjects in this group are African Americans, the majority are women, and the free insulin level in this group is also about twice that of the other two groups. However, this counter-regulatory hormone, similar to that in previous reports (</offsets><xref ref-type="bibr" rid="r5"><offsets xml_i="14869" xml_f="14870" txt_i="9793" txt_f="9794">5</offsets></xref><offsets xml_i="14877" xml_f="14878" txt_i="9794" txt_f="9795">,</offsets><xref ref-type="bibr" rid="r16"><offsets xml_i="14910" xml_f="14912" txt_i="9795" txt_f="9797">16</offsets></xref><offsets xml_i="14919" xml_f="14920" txt_i="9797" txt_f="9798">,</offsets><xref ref-type="bibr" rid="r17"><offsets xml_i="14952" xml_f="14954" txt_i="9798" txt_f="9800">17</offsets></xref><offsets xml_i="14961" xml_f="15289" txt_i="9800" txt_f="10128">), is still twofold higher than the baseline value. All measured parameters reached their near-normal values at recovery, with total ketone bodies reaching ∼3.5 mmol/l. Of interest was the FFA level, which at recovery was about twice the normal value but consistent with elevated levels of FFA in diabetic patients without DKA (</offsets><xref ref-type="bibr" rid="r16"><offsets xml_i="15321" xml_f="15323" txt_i="10128" txt_f="10130">16</offsets></xref><offsets xml_i="15330" xml_f="15375" txt_i="10130" txt_f="10172">). The mean anion gap at recovery was &lt;12.</offsets></p><p><xref rid="f1" ref-type="fig"><offsets xml_i="15412" xml_f="15420" txt_i="10173" txt_f="10181">Figure 1</offsets></xref><offsets xml_i="15427" xml_f="15589" txt_i="10181" txt_f="10343"> demonstrates the kinetics of intravenous insulin after infusion in the three arms. This figure shows that infusion of insulin of 0.07 (no load) or 0.14 unit · kg</offsets><sup><offsets xml_i="15594" xml_f="15596" txt_i="10343" txt_f="10345">−1</offsets></sup><offsets xml_i="15602" xml_f="15606" txt_i="10345" txt_f="10349"> · h</offsets><sup><offsets xml_i="15611" xml_f="15613" txt_i="10349" txt_f="10351">−1</offsets></sup><offsets xml_i="15619" xml_f="15798" txt_i="10351" txt_f="10530"> (twice no load) without an initial bolus resulted in peaks of 66 and 202 μU/ml, respectively, whereas the use of an intravenous bolus of 0.07 unit/kg followed by a 0.07 unit · kg</offsets><sup><offsets xml_i="15803" xml_f="15805" txt_i="10530" txt_f="10532">−1</offsets></sup><offsets xml_i="15811" xml_f="15815" txt_i="10532" txt_f="10536"> · h</offsets><sup><offsets xml_i="15820" xml_f="15822" txt_i="10536" txt_f="10538">−1</offsets></sup><offsets xml_i="15828" xml_f="16132" txt_i="10538" txt_f="10842"> infusion resulted in peak insulin of ∼460 μU/ml at 5 min, which reached a plateau level of ∼86 μU/ml in 30 min. It is also of interest that plateau levels of insulin for both the load and no load groups are not significantly different from 60 to 120 min. However, the twice no load group (0.14 unit · kg</offsets><sup><offsets xml_i="16137" xml_f="16139" txt_i="10842" txt_f="10844">−1</offsets></sup><offsets xml_i="16145" xml_f="16149" txt_i="10844" txt_f="10848"> · h</offsets><sup><offsets xml_i="16154" xml_f="16156" txt_i="10848" txt_f="10850">−1</offsets></sup><offsets xml_i="16162" xml_f="16322" txt_i="10850" txt_f="11010">, which is ∼10 units/h of insulin in a 70-kg patient) maintained higher levels of insulin during 30–120 min of infusion than those of the load or no load group.</offsets></p></sec><sec><title><offsets xml_i="16344" xml_f="16401" txt_i="11012" txt_f="11069">Effect of various doses of insulin on recovery parameters</offsets></title><p><xref ref-type="table" rid="t3"><offsets xml_i="16444" xml_f="16451" txt_i="11070" txt_f="11077">Table 3</offsets></xref><offsets xml_i="16458" xml_f="16581" txt_i="11077" txt_f="11200"> demonstrates the outcome recovery data for DKA, depicting the time that predetermined values were reached for glucose, HCO</offsets><sub><offsets xml_i="16586" xml_f="16587" txt_i="11200" txt_f="11201">3</offsets></sub><sup><offsets xml_i="16598" xml_f="16599" txt_i="11201" txt_f="11202">−</offsets></sup><offsets xml_i="16605" xml_f="17148" txt_i="11202" txt_f="11745">, and pH. The results suggested no significant differences in these values for the three doses of insulin, but 5 of 12 patients in the no load group required additional insulin for control of their blood glucose. The length of hospitalization was not significantly different among the groups, there were no complications in any of the groups, and no deaths occurred in this cohort. No hypokalemia was noted in any treatment group. The potassium nadirs were 4.3, 4.2, and 3.7 mEq/l in the load, no load, and twice no load groups, respectively (</offsets><xref rid="f2" ref-type="fig"><offsets xml_i="17178" xml_f="17184" txt_i="11745" txt_f="11751">Fig. 2</offsets></xref><offsets xml_i="17191" xml_f="17193" txt_i="11751" txt_f="11753">).</offsets></p><p><xref ref-type="table" rid="t4"><offsets xml_i="17232" xml_f="17239" txt_i="11754" txt_f="11761">Table 4</offsets></xref><offsets xml_i="17246" xml_f="17600" txt_i="11761" txt_f="12115"> shows estimates of the slopes for glucose, venous pH, ketones, FFAs, bicarbonate, and cortisol during the first 8 h of therapy in the three insulin therapy groups. The response of serum bicarbonate and cortisol showed no differences among the treatment groups. However, the slopes for glucose, venous pH, ketones, and FFAs varied among treatment groups.</offsets></p></sec></sec><sec><title><offsets xml_i="17628" xml_f="17639" txt_i="12118" txt_f="12129">CONCLUSIONS</offsets></title><p><offsets xml_i="17650" xml_f="17740" txt_i="12130" txt_f="12220">Although numerous studies have effectively used low-dose insulin in the treatment of DKA (</offsets><xref ref-type="bibr" rid="r3"><offsets xml_i="17771" xml_f="17772" txt_i="12220" txt_f="12221">3</offsets></xref><offsets xml_i="17779" xml_f="17780" txt_i="12221" txt_f="12222">,</offsets><xref ref-type="bibr" rid="r9"><offsets xml_i="17811" xml_f="17812" txt_i="12222" txt_f="12223">9</offsets></xref><offsets xml_i="17819" xml_f="17820" txt_i="12223" txt_f="12224">,</offsets><xref ref-type="bibr" rid="r18"><offsets xml_i="17852" xml_f="17854" txt_i="12224" txt_f="12226">18</offsets></xref><offsets xml_i="17861" xml_f="18057" txt_i="12226" txt_f="12422">), there are no data from a prospective randomized study evaluating an insulin bolus (0.07 U/kg) compared with no bolus in conjunction with an infusion of low-dose insulin (0.07 vs. 0.14 unit · kg</offsets><sup><offsets xml_i="18062" xml_f="18064" txt_i="12422" txt_f="12424">−1</offsets></sup><offsets xml_i="18070" xml_f="18074" txt_i="12424" txt_f="12428"> · h</offsets><sup><offsets xml_i="18079" xml_f="18081" txt_i="12428" txt_f="12430">−1</offsets></sup><offsets xml_i="18087" xml_f="18278" txt_i="12430" txt_f="12621">). Previous studies have demonstrated that although 0.1 unit/h of insulin in patients with DKA can effectively inhibit lipolysis, this dose will only suppress hepatic gluconeogenesis by 50% (</offsets><xref ref-type="bibr" rid="r11"><offsets xml_i="18310" xml_f="18312" txt_i="12621" txt_f="12623">11</offsets></xref><offsets xml_i="18319" xml_f="18321" txt_i="12623" txt_f="12625">).</offsets></p><p><offsets xml_i="18328" xml_f="18417" txt_i="12626" txt_f="12715">We had previously shown that an intermediate dose of insulin of 0.1 unit · kg body weight</offsets><sup><offsets xml_i="18422" xml_f="18424" txt_i="12715" txt_f="12717">−1</offsets></sup><offsets xml_i="18430" xml_f="18434" txt_i="12717" txt_f="12721"> · h</offsets><sup><offsets xml_i="18439" xml_f="18441" txt_i="12721" txt_f="12723">−1</offsets></sup><offsets xml_i="18447" xml_f="18608" txt_i="12723" txt_f="12884"> (equivalent of 7 units/h of insulin in a 70-kg patient) by intravenous infusion was much more effective than a dose by the subcutaneous or intramuscular route (</offsets><xref ref-type="bibr" rid="r4"><offsets xml_i="18639" xml_f="18640" txt_i="12884" txt_f="12885">4</offsets></xref><offsets xml_i="18647" xml_f="18851" txt_i="12885" txt_f="13089">). In these studies we used a priming dose. In addition, in a selected case report we have used as little as 6 units/h for a patient with modest DKA with further maintenance of euglycemia by 1–2 units/h (</offsets><xref ref-type="bibr" rid="r14"><offsets xml_i="18883" xml_f="18885" txt_i="13089" txt_f="13091">14</offsets></xref><offsets xml_i="18892" xml_f="18960" txt_i="13091" txt_f="13159">). However, a bolus dose of insulin preceded the low-dose infusion (</offsets><xref ref-type="bibr" rid="r19"><offsets xml_i="18992" xml_f="18994" txt_i="13159" txt_f="13161">19</offsets></xref><offsets xml_i="19001" xml_f="19083" txt_i="13161" txt_f="13243">). Furthermore, a priming dose has not been used for pediatric patients with DKA (</offsets><xref ref-type="bibr" rid="r10"><offsets xml_i="19115" xml_f="19117" txt_i="13243" txt_f="13245">10</offsets></xref><offsets xml_i="19124" xml_f="19218" txt_i="13245" txt_f="13339">) and has not been recommended in the pediatric age-group in the latest ADA consensus report (</offsets><xref ref-type="bibr" rid="r12"><offsets xml_i="19250" xml_f="19252" txt_i="13339" txt_f="13341">12</offsets></xref><offsets xml_i="19259" xml_f="19387" txt_i="13341" txt_f="13469">). Deleterious outcomes with the use of bolus insulin in this group may include hypokalemia as well as possible cerebral edema (</offsets><xref ref-type="bibr" rid="r12"><offsets xml_i="19419" xml_f="19421" txt_i="13469" txt_f="13471">12</offsets></xref><offsets xml_i="19428" xml_f="19430" txt_i="13471" txt_f="13473">).</offsets></p><p><offsets xml_i="19437" xml_f="19603" txt_i="13474" txt_f="13640">In summary, our study suggests that the use of a bolus or priming dose of insulin is not necessary when an adequate continuous insulin infusion such as 0.14 unit · kg</offsets><sup><offsets xml_i="19608" xml_f="19610" txt_i="13640" txt_f="13642">−1</offsets></sup><offsets xml_i="19616" xml_f="19620" txt_i="13642" txt_f="13646"> · h</offsets><sup><offsets xml_i="19625" xml_f="19627" txt_i="13646" txt_f="13648">−1</offsets></sup><offsets xml_i="19633" xml_f="19711" txt_i="13648" txt_f="13726"> (or 10 units/h in a 70-kg patient) is used. However, a dose of 0.07 unit · kg</offsets><sup><offsets xml_i="19716" xml_f="19718" txt_i="13726" txt_f="13728">−1</offsets></sup><offsets xml_i="19724" xml_f="19728" txt_i="13728" txt_f="13732"> · h</offsets><sup><offsets xml_i="19733" xml_f="19735" txt_i="13732" txt_f="13734">−1</offsets></sup><offsets xml_i="19741" xml_f="19849" txt_i="13734" txt_f="13842"> without priming is not adequate to obtain desired changes in glucose without supplemental doses of insulin.</offsets></p></sec></body><back><ack><p>This study was supported in part by U.S. Public Health Service Grant RR00211 (to the General Clinical Research Center) and by Grant DK07405 and Training Grant AM070884 from the National Institutes of Health.</p><p>The assistance of Drs. Dale Childress and James Peyton in assessment of some of the data during their training is greatly appreciated. The authors appreciate the secretarial assistance of Brenda Scott on this manuscript.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal">Alberti KGMM, Hockaday TDR, Turner RC: Small doses of intramuscular insulin in the treatment of diabetic “coma.” <source>Lancet</source> <volume>5</volume>:<fpage>515</fpage>–522, <year>1973</year></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal">Kitabchi AE, Ayyagari V, Guerra SM: The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. <source>Ann Intern Med</source> <volume>84</volume>:<fpage>633</fpage>–638, <year>1976</year><pub-id pub-id-type="pmid">820228</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal">Wagner A, Risse A, Brill HL, Wienhausen-Wilke V, Rottmann M, Sondern K, Angelkort B: Therapy of severe diabetic ketoacidosis: zero-mortality under very-low-dose insulin application. <source>Diabetes Care</source> <volume>22</volume>:<fpage>674</fpage>–677, <year>1999</year><pub-id pub-id-type="pmid">10332664</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal">Fisher JN, Shahshahani MN, Kitabchi AE: Diabetic ketoacidosis: low-dose insulin therapy by various routes. <source>N Engl J Med</source> <volume>297</volume>:<fpage>238</fpage>–247, <year>1977</year><pub-id pub-id-type="pmid">406561</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal">Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM: Management of hyperglycemic crises in patients with diabetes. <source>Diabetes Care</source> <volume>24</volume>:<fpage>131</fpage>–153, <year>2001</year><pub-id pub-id-type="pmid">11194218</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal">American Diabetes Association Position Paper: Hyperglycemic crisis in patients with diabetes mellitus. <source>Diabetes Care</source> <volume>19</volume>:<fpage>S82</fpage>–S90, <year>2001</year></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal">Morris LR, Murphy MB, Kitabchi AE: Bicarbonate therapy in severe diabetic ketoacidosis. <source>Ann Intern Med</source> <volume>105</volume>:<fpage>836</fpage>–840, <year>1986</year><pub-id pub-id-type="pmid">3096181</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal">Sacks HS, Shahshahani MN, Kitabchi AE, Fisher JN, Young RT: Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion. <source>Ann Intern Med</source> <volume>90</volume>:<fpage>36</fpage>–42, <year>1979</year><pub-id pub-id-type="pmid">105656</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal">Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA: Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. <source>Diabetes Care</source> <volume>29</volume>:<fpage>2739</fpage>–2748, <year>2006</year><pub-id pub-id-type="pmid">17130218</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal">Burghen GA, Etteldorf JN, Fisher JN, Kitabchi AE: Comparison of high-dose to low-dose insulin by continuous intravenous infusion in the treatment of diabetic ketoacidosis in children. <source>Diabetes Care</source> <volume>3</volume>:<fpage>15</fpage>–20, <year>1980</year><pub-id pub-id-type="pmid">6773725</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal">Luzi L, Barrett EJ, Groop LC, Ferrannini E, De Fronzo RA: Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. <source>Diabetes</source> <volume>37</volume>:<fpage>1470</fpage>–1477, <year>1988</year><pub-id pub-id-type="pmid">3141236</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal">Wolfsdorf J, Glaser N, Sperling M: Diabetic ketoacidosis in Infants, children, and adolescents: a consensus statement from the American Diabetes Association. <source>Diabetes Care</source> <volume>29</volume>:<fpage>1150</fpage>–1159, <year>2006</year><pub-id pub-id-type="pmid">16644656</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal">Kitabchi AE, Umpierrez G, Fisher JN, Murphy MB, Stentz F: Thirty years of personal experience in 12 hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. <source>J Clin Endocrinol Metab</source> <volume>92</volume>:<fpage>1541</fpage>–1552, <year>2008</year></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal">Kuzuya H, Blix PM, Horwitz DL, Steiner DF, and Rubenstein AH: Determination of free and total insulin and C-peptide in insulin-treated diabetics. <source>Diabetes</source> <volume>26</volume>:<fpage>22</fpage>–29, <year>1977</year><pub-id pub-id-type="pmid">830562</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal">Lawson V, Young R, Kitabchi AE: Maturity-onset diabetes of the young: an illustrative case for control of diabetes and hormonal normalization with dietary management. <source>Diabetes Care</source> <volume>4</volume>:<fpage>108</fpage>–112, <year>1981</year><pub-id pub-id-type="pmid">7472111</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal">Stentz FB, Umpierrez GE, Cuervo R Kitabchi AE: Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. <source>Diabetes</source> <volume>53</volume>:<fpage>2079</fpage>–2086, <year>2004</year><pub-id pub-id-type="pmid">15277389</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal">Schade DS, Eaton RP: The temporal relationship between endogenously secreted stress hormones and metabolic decompensation in diabetic man. <source>J Clin Endocrinol Metab</source> <volume>50</volume>:<fpage>131</fpage>–136, <year>1980</year><pub-id pub-id-type="pmid">7350176</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="other">Kitabchi AE, Fisher JN, Murphy MB, Rumbak MJ: Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In <source>Joslin's Diabetes Mellitus.</source> 13th ed. Kahn CR, Weir GC, Eds. Baltimore, Williams &amp; Wilkins <year>1994</year>, p. <fpage>738</fpage>–770</citation></ref><ref id="r19"><label>19</label><citation citation-type="other">Kitabchi AE: Low-dose insulin therapy in diabetic ketoacidosis: fact or fiction. In <source>Diabetes Metabolism Reviews.</source> DeFronzo R, Ed. New York, John Wiley &amp; Sons, <year>1989</year>, p. <fpage>337</fpage>–363</citation></ref></ref-list></back><floats-wrap><fig position="float" id="f1"><label>Figure 1</label><caption><p>Kinetics of three doses of low-dose insulin in patients with DKA.</p></caption><graphic xlink:href="zdc0110872490001"></graphic></fig><fig position="float" id="f2"><label>Figure 2</label><caption><p>Changes in hourly serum potassium with three low-dose insulin regimens in the treatment of DKA.</p></caption><graphic xlink:href="zdc0110872490002"></graphic></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><p>Demographics and clinical data of 37 patients with DKA with three intravenous insulin protocols</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="bottom"></th><th colspan="1" rowspan="1" align="center" valign="bottom">Load</th><th colspan="1" rowspan="1" align="center" valign="bottom">No load</th><th colspan="1" rowspan="1" align="center" valign="bottom">Twice no load</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>n</italic></td><td colspan="1" rowspan="1" align="center" valign="top">12</td><td colspan="1" rowspan="1" align="center" valign="top">12</td><td colspan="1" rowspan="1" align="center" valign="top">13</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Age (years)</td><td colspan="1" rowspan="1" align="center" valign="top">28.6 ± 2.3 (19–44)</td><td colspan="1" rowspan="1" align="center" valign="top">37.3 ± 4.2 (20–66)</td><td colspan="1" rowspan="1" align="center" valign="top">31.8 ± 2.8 (17–50)</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Sex</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Female</td><td colspan="1" rowspan="1" align="center" valign="top">4</td><td colspan="1" rowspan="1" align="center" valign="top">9</td><td colspan="1" rowspan="1" align="center" valign="top">6</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Male</td><td colspan="1" rowspan="1" align="center" valign="top">8</td><td colspan="1" rowspan="1" align="center" valign="top">3</td><td colspan="1" rowspan="1" align="center" valign="top">7</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Race</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Caucasian</td><td colspan="1" rowspan="1" align="center" valign="top">4</td><td colspan="1" rowspan="1" align="center" valign="top">0</td><td colspan="1" rowspan="1" align="center" valign="top">4</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    African American</td><td colspan="1" rowspan="1" align="center" valign="top">8</td><td colspan="1" rowspan="1" align="center" valign="top">12</td><td colspan="1" rowspan="1" align="center" valign="top">9</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">BMI (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1" align="center" valign="top">22.1 ± 1.6</td><td colspan="1" rowspan="1" align="center" valign="top">24.6 ± 2.6</td><td colspan="1" rowspan="1" align="center" valign="top">22.1 ± 1.3</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Duration of diabetes (years)</td><td colspan="1" rowspan="1" align="center" valign="top">8.5 ± 1.7</td><td colspan="1" rowspan="1" align="center" valign="top">5.6 ± 2.0</td><td colspan="1" rowspan="1" align="center" valign="top">8.0 ± 2.5</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Treatment</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    None</td><td colspan="1" rowspan="1" align="center" valign="top">2</td><td colspan="1" rowspan="1" align="center" valign="top">5</td><td colspan="1" rowspan="1" align="center" valign="top">2</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Diet</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top">2</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Insulin</td><td colspan="1" rowspan="1" align="center" valign="top">10</td><td colspan="1" rowspan="1" align="center" valign="top">7</td><td colspan="1" rowspan="1" align="center" valign="top">9</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Precipitating factor</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Lack of insulin</td><td colspan="1" rowspan="1" align="center" valign="top">6</td><td colspan="1" rowspan="1" align="center" valign="top">6</td><td colspan="1" rowspan="1" align="center" valign="top">5</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Infection</td><td colspan="1" rowspan="1" align="center" valign="top">3</td><td colspan="1" rowspan="1" align="center" valign="top">4</td><td colspan="1" rowspan="1" align="center" valign="top">5</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Other</td><td colspan="1" rowspan="1" align="center" valign="top">3</td><td colspan="1" rowspan="1" align="center" valign="top">2</td><td colspan="1" rowspan="1" align="center" valign="top">3</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Blood pressure</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Systolic (mmHg)</td><td colspan="1" rowspan="1" align="center" valign="top">125 ± 8</td><td colspan="1" rowspan="1" align="center" valign="top">127 ± 8</td><td colspan="1" rowspan="1" align="center" valign="top">128 ± 5</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Diastolic (mmHg)</td><td colspan="1" rowspan="1" align="center" valign="top">66 ± 3</td><td colspan="1" rowspan="1" align="center" valign="top">81 ± 4</td><td colspan="1" rowspan="1" align="center" valign="top">82 ± 4</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Pulse (beats/min)</td><td colspan="1" rowspan="1" align="center" valign="top">109 ± 3</td><td colspan="1" rowspan="1" align="center" valign="top">108 ± 5</td><td colspan="1" rowspan="1" align="center" valign="top">113 ± 6</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Respiratory rate (per min)</td><td colspan="1" rowspan="1" align="center" valign="top">27 ± 1.0</td><td colspan="1" rowspan="1" align="center" valign="top">24 ± 1.0</td><td colspan="1" rowspan="1" align="center" valign="top">29 ± 1.0</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Mental status</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Alert</td><td colspan="1" rowspan="1" align="center" valign="top">9</td><td colspan="1" rowspan="1" align="center" valign="top">5</td><td colspan="1" rowspan="1" align="center" valign="top">5</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Drowsy</td><td colspan="1" rowspan="1" align="center" valign="top">3</td><td colspan="1" rowspan="1" align="center" valign="top">5</td><td colspan="1" rowspan="1" align="center" valign="top">7</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Stupor</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top">1</td><td colspan="1" rowspan="1" align="center" valign="top">1</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    Comatose</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top">1</td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr></tbody></table><table-wrap-foot><fn><p>Data are means ± SEM, means ± SEM (range), or <italic>n</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><p>Biochemical and hormonal data at baseline and recovery of patients with DKA receiving three insulin protocols</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom"></th><th colspan="2" rowspan="1" align="center" valign="bottom">Load
<hr></hr></th><th colspan="2" rowspan="1" align="center" valign="bottom">No load
<hr></hr></th><th colspan="2" rowspan="1" align="center" valign="bottom">Twice no load
<hr></hr></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom">Baseline</th><th colspan="1" rowspan="1" align="center" valign="bottom">Recovery</th><th colspan="1" rowspan="1" align="center" valign="bottom">Baseline</th><th colspan="1" rowspan="1" align="center" valign="bottom">Recovery</th><th colspan="1" rowspan="1" align="center" valign="bottom">Baseline</th><th colspan="1" rowspan="1" align="center" valign="bottom">Recovery</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top">Sodium (mEq/l)</td><td colspan="1" rowspan="1" align="center" valign="top">131 ± 2</td><td colspan="1" rowspan="1" align="center" valign="top">137 ± 1.1</td><td colspan="1" rowspan="1" align="center" valign="top">137 ± 3</td><td colspan="1" rowspan="1" align="center" valign="top">136 ± 3.2</td><td colspan="1" rowspan="1" align="center" valign="top">131 ± 1</td><td colspan="1" rowspan="1" align="center" valign="top">136 ± 1.8</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Potassium (mEq/l)</td><td colspan="1" rowspan="1" align="center" valign="top">5.4 ± 0.3</td><td colspan="1" rowspan="1" align="center" valign="top">4.0 ± 0.14</td><td colspan="1" rowspan="1" align="center" valign="top">4.8 ± 0.2</td><td colspan="1" rowspan="1" align="center" valign="top">3.8 ± 0.14</td><td colspan="1" rowspan="1" align="center" valign="top">5.5 ± 0.3</td><td colspan="1" rowspan="1" align="center" valign="top">3.8 ± 0.09</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Bicarbonate (mEq/l)</td><td colspan="1" rowspan="1" align="center" valign="top">6.7 ± 0.7</td><td colspan="1" rowspan="1" align="center" valign="top">17.8 ± 1.0</td><td colspan="1" rowspan="1" align="center" valign="top">5.9 ± 0.8</td><td colspan="1" rowspan="1" align="center" valign="top">16.2 ± 0.43</td><td colspan="1" rowspan="1" align="center" valign="top">4.9 ± 0.5</td><td colspan="1" rowspan="1" align="center" valign="top">16.0 ± 0.35</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Glucose (mg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">578 ± 64</td><td colspan="1" rowspan="1" align="center" valign="top">162 ± 12</td><td colspan="1" rowspan="1" align="center" valign="top">459 ± 38</td><td colspan="1" rowspan="1" align="center" valign="top">133 ± 15</td><td colspan="1" rowspan="1" align="center" valign="top">522 ± 47</td><td colspan="1" rowspan="1" align="center" valign="top">110 ± 9</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Blood urea nitrogen (mg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">29 ± 6</td><td colspan="1" rowspan="1" align="center" valign="top">16.3 ± 3.8</td><td colspan="1" rowspan="1" align="center" valign="top">21 ± 4</td><td colspan="1" rowspan="1" align="center" valign="top">16.3 ± 4.2</td><td colspan="1" rowspan="1" align="center" valign="top">22 ± 2</td><td colspan="1" rowspan="1" align="center" valign="top">17.2 ± 2.9</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Anion gap (mEq/l)</td><td colspan="1" rowspan="1" align="center" valign="top">27 ± 1</td><td colspan="1" rowspan="1" align="center" valign="top">11.3 ± 1.8</td><td colspan="1" rowspan="1" align="center" valign="top">24 ± 2</td><td colspan="1" rowspan="1" align="center" valign="top">7.8 ± 1.7</td><td colspan="1" rowspan="1" align="center" valign="top">27 ± 2</td><td colspan="1" rowspan="1" align="center" valign="top">10.3 ± 1.7</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">pH</td><td colspan="1" rowspan="1" align="center" valign="top">7.12 ± 0.03</td><td colspan="1" rowspan="1" align="center" valign="top">7.3 ± 0.01</td><td colspan="1" rowspan="1" align="center" valign="top">7.15 ± 00.03</td><td colspan="1" rowspan="1" align="center" valign="top">7.31 ± 0.01</td><td colspan="1" rowspan="1" align="center" valign="top">7.07 ± 0.02</td><td colspan="1" rowspan="1" align="center" valign="top">7.32 ± 0.01</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">β-Hydroxybutyrate (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">10.5 ± 1.1</td><td colspan="1" rowspan="1" align="center" valign="top">2.4 ± 0.5</td><td colspan="1" rowspan="1" align="center" valign="top">8.8 ± 0.9</td><td colspan="1" rowspan="1" align="center" valign="top">2.7 ± 0.6</td><td colspan="1" rowspan="1" align="center" valign="top">10.5 ± 1.2</td><td colspan="1" rowspan="1" align="center" valign="top">2.5 ± 0.4</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Acetoacetate (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">2.5 ± 0.3</td><td colspan="1" rowspan="1" align="center" valign="top">1.06 ± 0.19</td><td colspan="1" rowspan="1" align="center" valign="top">2.6 ± 0.3</td><td colspan="1" rowspan="1" align="center" valign="top">1.20 ± 0.34</td><td colspan="1" rowspan="1" align="center" valign="top">2.4 ± 0.4</td><td colspan="1" rowspan="1" align="center" valign="top">0.90 ± 0.20</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Total ketones (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">13.0 ± 1.1</td><td colspan="1" rowspan="1" align="center" valign="top">3.5 ± 0.7</td><td colspan="1" rowspan="1" align="center" valign="top">11.4 ± 1.0</td><td colspan="1" rowspan="1" align="center" valign="top">3.9 ± 0.9</td><td colspan="1" rowspan="1" align="center" valign="top">13.2 ± 1.5</td><td colspan="1" rowspan="1" align="center" valign="top">3.5 ± 0.5</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Pyruvate (mg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">0.6 ± 0.1</td><td colspan="1" rowspan="1" align="center" valign="top">0.34 ± 0.06</td><td colspan="1" rowspan="1" align="center" valign="top">0.7 ± 0.3</td><td colspan="1" rowspan="1" align="center" valign="top">0.35 ± 0.08</td><td colspan="1" rowspan="1" align="center" valign="top">0.9 ± 0.2</td><td colspan="1" rowspan="1" align="center" valign="top">0.65 ± 0.09<xref ref-type="table-fn" rid="t2fn1">*</xref></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Lactate (mg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">18.3 ± 3.8</td><td colspan="1" rowspan="1" align="center" valign="top">7.9 ± 1.3</td><td colspan="1" rowspan="1" align="center" valign="top">13.7 ± 1.6</td><td colspan="1" rowspan="1" align="center" valign="top">8.3 ± 0.8</td><td colspan="1" rowspan="1" align="center" valign="top">19.5 ± 2.3</td><td colspan="1" rowspan="1" align="center" valign="top">10.7 ± 2.1</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Free fatty acid (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">1.92 ± 0.18</td><td colspan="1" rowspan="1" align="center" valign="top">0.74 ± 0.09</td><td colspan="1" rowspan="1" align="center" valign="top">1.83 ± 0.23</td><td colspan="1" rowspan="1" align="center" valign="top">1.00 ± 0.17</td><td colspan="1" rowspan="1" align="center" valign="top">2.14 ± 0.10</td><td colspan="1" rowspan="1" align="center" valign="top">1.92 ± 0.10</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Free insulin (μU/ml)</td><td colspan="1" rowspan="1" align="center" valign="top">4.17 ± 1.82</td><td colspan="1" rowspan="1" align="center" valign="top">ND</td><td colspan="1" rowspan="1" align="center" valign="top">6.66 ± 1.76</td><td colspan="1" rowspan="1" align="center" valign="top">ND</td><td colspan="1" rowspan="1" align="center" valign="top">3.69 ± 1.69</td><td colspan="1" rowspan="1" align="center" valign="top">ND</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">C-peptide (pmol/ml)</td><td colspan="1" rowspan="1" align="center" valign="top">0.08 ± 0.07</td><td colspan="1" rowspan="1" align="center" valign="top">ND</td><td colspan="1" rowspan="1" align="center" valign="top">0.14 ± 0.1</td><td colspan="1" rowspan="1" align="center" valign="top">ND</td><td colspan="1" rowspan="1" align="center" valign="top">0.11 ± 0.05</td><td colspan="1" rowspan="1" align="center" valign="top">ND</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Cortisol (μg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">72 ± 12</td><td colspan="1" rowspan="1" align="center" valign="top">27.1 ± 4.7</td><td colspan="1" rowspan="1" align="center" valign="top">54 ± 11</td><td colspan="1" rowspan="1" align="center" valign="top">26.9 ± 9.6</td><td colspan="1" rowspan="1" align="center" valign="top">83 ± 12</td><td colspan="1" rowspan="1" align="center" valign="top">33.2 ± 5.8</td></tr></tbody></table><table-wrap-foot><fn><p>Data are means ± SEM.</p></fn><fn id="t2fn1"><label>*</label><p><italic>P</italic> &lt; 0.05, compared with the other groups. ND, not done.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><p>Outcome data for three doses of intravenous insulin in DKA</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="bottom"></th><th colspan="1" rowspan="1" align="center" valign="bottom">Load</th><th colspan="1" rowspan="1" align="center" valign="bottom">No load</th><th colspan="1" rowspan="1" align="center" valign="bottom">Twice no load</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>n</italic></td><td colspan="1" rowspan="1" align="center" valign="top">12</td><td colspan="1" rowspan="1" align="center" valign="top">12</td><td colspan="1" rowspan="1" align="center" valign="top">13</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Hours to glucose control (≤250 mg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">4.33 ± 0.66</td><td colspan="1" rowspan="1" align="center" valign="top">4.67 ± 0.83</td><td colspan="1" rowspan="1" align="center" valign="top">3.69 ± 0.46</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Hours to bicarbonate control (≥15 mEq/l)</td><td colspan="1" rowspan="1" align="center" valign="top">10.3 ± 1.9</td><td colspan="1" rowspan="1" align="center" valign="top">13.8 ± 2.8</td><td colspan="1" rowspan="1" align="center" valign="top">9.62 ± 1.1</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Hours to pH control (≥7.3)</td><td colspan="1" rowspan="1" align="center" valign="top">8.33 ± 1.88</td><td colspan="1" rowspan="1" align="center" valign="top">8.08 ± 1.74</td><td colspan="1" rowspan="1" align="center" valign="top">8.46 ± 1.11</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Hours to recovery</td><td colspan="1" rowspan="1" align="center" valign="top">11.1 ± 1.7</td><td colspan="1" rowspan="1" align="center" valign="top">13.8 ± 2.8</td><td colspan="1" rowspan="1" align="center" valign="top">10.2 ± 1.1</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Insulin dose to recovery (units)</td><td colspan="1" rowspan="1" align="center" valign="top">48.2 ± 9.5</td><td colspan="1" rowspan="1" align="center" valign="top">81.3 ± 18.5</td><td colspan="1" rowspan="1" align="center" valign="top">80.0 ± 9.5</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Intravenous fluid given (ml)</td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td><td colspan="1" rowspan="1" align="center" valign="top"></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    First 8 h</td><td colspan="1" rowspan="1" align="center" valign="top">3,740 ± 410</td><td colspan="1" rowspan="1" align="center" valign="top">4,210 ± 440</td><td colspan="1" rowspan="1" align="center" valign="top">3,570 ± 250</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">    First 24 h</td><td colspan="1" rowspan="1" align="center" valign="top">7,170 ± 600</td><td colspan="1" rowspan="1" align="center" valign="top">7,950 ± 490</td><td colspan="1" rowspan="1" align="center" valign="top">7,510 ± 300</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Complications</td><td colspan="1" rowspan="1" align="center" valign="top">0</td><td colspan="1" rowspan="1" align="center" valign="top">0</td><td colspan="1" rowspan="1" align="center" valign="top">0</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Deaths</td><td colspan="1" rowspan="1" align="center" valign="top">0</td><td colspan="1" rowspan="1" align="center" valign="top">0</td><td colspan="1" rowspan="1" align="center" valign="top">0</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Days in hospital</td><td colspan="1" rowspan="1" align="center" valign="top">5.9 ± 0.7</td><td colspan="1" rowspan="1" align="center" valign="top">4.7 ± 0.6</td><td colspan="1" rowspan="1" align="center" valign="top">6.9 ± 0.7</td></tr></tbody></table><table-wrap-foot><fn><p>Data are means ± SEM.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t4"><label>Table 4</label><caption><p>Slope estimates for clinical and hormonal responses to therapy over the first 8 h</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom">Parameter</th><th colspan="2" rowspan="1" align="center" valign="bottom">Load group
<hr></hr></th><th colspan="2" rowspan="1" align="center" valign="bottom">No load group
<hr></hr></th><th colspan="2" rowspan="1" align="center" valign="bottom">Twice no load group
<hr></hr></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom">Initial value<xref ref-type="table-fn" rid="t4fn1">*</xref></th><th colspan="1" rowspan="1" align="center" valign="bottom">Estimate of slope<xref ref-type="table-fn" rid="t4fn2">†</xref></th><th colspan="1" rowspan="1" align="center" valign="bottom">Initial value<xref ref-type="table-fn" rid="t4fn1">*</xref></th><th colspan="1" rowspan="1" align="center" valign="bottom">Estimate of slope<xref ref-type="table-fn" rid="t4fn2">†</xref></th><th colspan="1" rowspan="1" align="center" valign="bottom">Initial value<xref ref-type="table-fn" rid="t4fn1">*</xref></th><th colspan="1" rowspan="1" align="center" valign="bottom">Estimate of slope<xref ref-type="table-fn" rid="t4fn2">†</xref></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top">Glucose (mg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">578.1 ± 63.7</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−86.49<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">459.2 ± 38.2</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−52.22<sup>b</sup></td><td colspan="1" rowspan="1" align="center" valign="top">521.9 ± 47.0</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−77.67<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Venous pH</td><td colspan="1" rowspan="1" align="center" valign="top">7.1 ± 0.03</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.029<sup>a,b</sup></td><td colspan="1" rowspan="1" align="center" valign="top">7.13 ± 0.03</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.025<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">7.04 ± 0.02</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.042<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Ketones (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">12.98 ± 1.14</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−1.92<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">10.33 ± 1.3</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−0.93<sup>b</sup></td><td colspan="1" rowspan="1" align="center" valign="top">13.17 ± 1.47</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−1.23<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">FFAs (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">1.92 ± 0.18</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.34<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">1.83 ± 0.23</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−0.21<sup>b</sup></td><td colspan="1" rowspan="1" align="center" valign="top">2.14 ± 0.10</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−0.26<sup>a,b</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Serum bicarbonate (mEq/l)</td><td colspan="1" rowspan="1" align="center" valign="top">6.7 ± 0.7</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.863<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">5.9 ± 0.8</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.551<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">4.9 ± 0.5</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.779<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Cortisol (μg/dl)</td><td colspan="1" rowspan="1" align="center" valign="top">71.8 ± 11.7</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−7.09<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">54.3 ± 10.5</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−4.40<sup>a</sup></td><td colspan="1" rowspan="1" align="center" valign="top">82.7 ± 12.2</td><td colspan="1" rowspan="1" align="char" char="." valign="top">−7.73<sup>a</sup></td></tr></tbody></table><table-wrap-foot><fn><p>Data are means ± SEM.</p></fn><fn id="t4fn1"><label>*</label><p>No significant differences noted in initial values.</p></fn><fn id="t4fn2"><label>†</label><p>In comparisons involving load, no load, and twice no load treatment groups, those slope estimates with the same superscript are not significantly different at <italic>P</italic> = 0.05.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>